These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23337420)

  • 1. GnRH agonist triggering: recent developments.
    Kol S; Humaidan P
    Reprod Biomed Online; 2013 Mar; 26(3):226-30. PubMed ID: 23337420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P; Papanikolaou EG; Tarlatzis BC
    Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives.
    Humaidan P; Papanikolaou EG; Kyrou D; Alsbjerg B; Polyzos NP; Devroey P; Fatemi HM
    Reprod Biomed Online; 2012 Feb; 24(2):134-41. PubMed ID: 22197130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symposium: Update on prediction and management of OHSS. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation.
    Kol S; Dor J
    Reprod Biomed Online; 2009 Jul; 19(1):59-60. PubMed ID: 19573291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
    Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?
    Lawrenz B; Humaidan P; Kol S; Fatemi HM
    Reprod Biomed Online; 2018 Jan; 36(1):75-77. PubMed ID: 29102428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
    Casper RF
    Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
    Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
    Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango?
    Kol S; Humaidan P
    Reprod Biomed Online; 2010 Nov; 21(5):590-2. PubMed ID: 20851052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?
    Orvieto R
    J Ovarian Res; 2015 Aug; 8():60. PubMed ID: 26293447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimulation syndrome.
    Itskovitz-Eldor J; Levron J; Kol S
    Clin Obstet Gynecol; 1993 Sep; 36(3):701-10. PubMed ID: 8403616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.